Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Next Previous
Trial Profile

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Registrational; Therapeutic Use
  • Acronyms FRESCO
  • Sponsors Hutchison MediPharma

Most Recent Events

  • 20 Sep 2024 According to media relesae published in Medicines and Healthcare products Regulatory Agency, they have approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal cancer on basis of FRESCO2 and FRESCO trial.
  • 14 May 2024 According to a Takeda media release, data from this and FRESCO-2 study will be presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
  • 09 Nov 2023 According to a HUTCHMED media release, Takeda received approval from the U.S. Food and Drug Administration ("FDA") for FRUZAQLA™ (fruquintinib), ) for previously treated metastatic colorectal cancer, based on data from FRESCO-2 and FRESCO trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top